Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injectorSarclisa administered via ...

Sandoz is offering treprostinil injection for subcutaneous administration to treat patients diagnosed with pulmonary arterial hypertension. Sandoz treprostinil injection was the first generic of ...

This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...

Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myelomaApproval based on multiple studies, including the ...

The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...

A person receives subcutaneous immunotherapy as an injection under the skin. This treatment method has shown similar effectiveness to intravenous (IV) infusions that healthcare professionals often use ...

A subcutaneous (SC) form of immune anticancer drug that can be administered in 1 to 2 minutes by injection into the skin has ...

− ENTYVIO Is the Only FDA-Approved Ulcerative Colitis Biologic That Offers the Choice of Intravenous or Subcutaneous Maintenance Therapy “With the FDA approval of subcutaneous ENTYVIO, patients and ...

Immunotherapy, exemplified by Opdivo, enhances cancer treatment by targeting malignant cells using the immune system, offering a more precise approach than traditional therapies. The FDA approved ...

For patients with metastatic non–small cell lung cancer (NSCLC), subcutaneous (SC) administration of pembrolizumab works just as well as standard intravenous (IV) administration, phase 3 data ...

A novel indwelling subcutaneous intrathecal catheter circumvented the complex spine anatomy of patients with spinal muscular atrophy (SMA), a challenge when giving nusinersen via intrathecal injection ...

Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector: Paris Tuesday, June 9, 2026, 16:00 Hrs [IST] The Europe ...